-The Times of India NEW DELHI: An analysis of bills from four reputed private hospitals in Delhi and NCR by the National Pharmaceutical Pricing Authority (NPPA) has revealed that they are making profits of up to 1,737% on drugs, consumables and diagnostics and that these three accounts for about 46% of a patient’s bill. The analysis, released on Tuesday, noted that “the major beneficiaries of profits in all these cases because of...
More »SEARCH RESULT
Total Matching Records found : 70
Cardiac stent price cap lowered further to Rs 28,000 -Rema Nagarajan
-The Times of India The National Pharmaceutical Pricing Authority on Monday revised the price of drug eluting stents (DES) downwards by about Rs 2,300 to just under Rs 28,000, while marginally raising the cap on bare metal stents from Rs 7,400 to Rs 7,660. These caps are excluding GST. With DES accounting for about 95% of all stents used in India, this means most stents will become cheaper. The authority, which had...
More »Dengue death: Fortis kept profit margin as high as 1,737 per cent, finds NPPA -Abantika Ghosh
-The Indian Express Aadya died of dengue at the hospital in September, and her family was charged almost Rs 16 lakh for a 15-day stay. New Delhi: Fortis Hospital, Gurgaon made a 1,737 per cent profit on drugs and other consumables that it billed the family of seven-year-old Aadya Singh, the drug pricing regulator has found in an analysis. Aadya died of dengue at the hospital in September, and her family was charged...
More »Cry to widen stent price cap -GS Mudur
-The Telegraph New Delhi: Health activists campaigning for affordable treatment on Wednesday urged the Narendra Modi government to resist "pressure" from foreign medical device makers and expand price caps to new classes of medical devices. The All India Drug Action Network (AIDAN), a consortium of non-government activists' groups, said it was concerned that a body of foreign medical device manufacturers had petitioned the US government seeking suspension or withdrawal of certain trade...
More »Why NPPA didn't wait for govt to make knee implants 'essential' -Rema Nagarajan
-The Times of India In a first for a medical device, the public interest provision in the Drug Price Control Order (DPCO) 2013 was used by the National Pharmaceutical Pricing Authority to cap the price of knee implants. The NPPA cited "exorbitant prices being charged from patients in a non-regulated market" and "a failed market system where asymmetry of information between patient and the doctor has resulted into unethical practices and...
More »
